2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult, Animal Model
PAPER

5859 Antibiotic Exposure Is associated with impaired Efficacy in CAR-T Patients and a Live Biotherapeutic Product Restores CAR-T efficacy in a preclinical model

Zeyang Li, PhD, Pamela S. Herrera, PhD2, Nathan Duong, BS3, Yuqing Chen, MS4, Jennifer Angelica Funes, MS5, Adhithi Rajagopalan, MD PhD6, Bintao Wang, BS, MS7, Arnab Chowdhury, MS8, Annie Xiao, MD9, Elizabeth Halvorsen, PhD10, Nicholas Beauchemin11, Christopher Ford12, Dennis Walling, MD, MMCI, FIDSA13, Matthew Henn, PhD14, Melody Smith, MD,MS15, L. Elizabeth Elizabeth Budde, MD PhD16, Joycelynne Palmer, PhD17, Scott E. James, MD,PhD18, Jenny Paredes, PhD19, Marcel R.M. van den Brink Jr, M.D., Ph.D.20
1 City of Hope National Medical Center, Duarte, California, United States
2 City of Hope National Medical Center, Duarte, California, United States
3 City of Hope National Medical Center, Duarte, California, United States
4 City of Hope National Medical Center, Duarte, California, United States
5 City of Hope National Medical Center, Duarte, California, United States
6 City of Hope National Medical Center, Duarte, California, United States
7 City of Hope National Medical Center, Duarte, California, United States
8 City of Hope National Medical Center, Duarte, California, United States
9 City of Hope National Medical Center, Duarte, California, United States
10 Seres Therapeutics, Cambridge, Massachusetts, United States
11 Seres Therapeutics, Cambridge, Massachusetts, United States
12 Seres Therapeutics, Cambridge, Massachusetts, United States
13 Seres Therapeutics, Cambridge, Massachusetts, United States
14 Seres Therapeutics, Cambridge, Massachusetts, United States
15 Stanford School of Medicine, Palo Alto, California, United States
16 City of Hope National Medical Center, Duarte, California, United States
17 City of Hope National Medical Center, Duarte, California, United States
18 City of Hope National Medical Center, Duarte, California, United States
19 City of Hope National Medical Center, Duarte, California, United States
20 City of Hope National Medical Center, Duarte, California, United States

Background 

Antibiotic exposure is commonly used during chimeric antigen receptor (CAR)-T cell therapy due to lymphodepletion-associated neutropenia and infectious complications. Peri-infusion antibiotic-associated disruption of the intestinal microbiome has been linked to reduced CAR-T efficacy and broad-spectrum antibiotic exposure has been associated with worse clinical outcomes. However, the effects of peri-infusion β-lactam and fluoroquinolone antibiotic exposure remain unclear. Here, we aim to investigate the association of peri-infusion β-lactam and fluoroquinolone antibiotic exposure with overall survival (OS) in patients receiving CD19-directed CAR-T therapy and evaluated representative antibiotics from these classes in a matched murine CAR-T model. Given the microbiome-disrupting effects of antibiotic exposure, we sought to establish an in vivo model to evaluate live biotherapeutic product (LBP)-mediated microbiome restoration during CAR-T therapy. We evaluated P3X, a research-grade formulation comprising 13 of the 16 bacterial strains in the investigational LBP SER-155, which was designed to improve gastrointestinal barrier integrity and restore gut microbiome homeostasis. 

Methods 

OS was retrospectively evaluated in adult patients receiving CD19-directed CAR-T therapy at City of Hope (COH) (2017-2025, n=566). Preclinical studies were performed using a BALB/c A20 lymphoma model treated with 1928z CD19 CAR-T cells. For the antibiotic exposure study, BALB/c mice received ampicillin (0.5 g/L) and enrofloxacin (0.25 g/L) in drinking water from day −8 relative to CAR-T cell infusion until the end of the study. Mice were harvested on day 10 after CAR-T cell infusion for flow cytometric analysis. For the P3X study, endogenous gut microbiota were depleted with ampicillin (0.5 g/L), vancomycin (0.5 g/L), neomycin (0.5 g/L), and metronidazole (1 g/L) in drinking water from day −18 to day −11 relative to CAR-T cell infusion, followed by daily oral administration of P3X from day −11 to day −6. Whole metagenomic sequencing (WMS) and taxonomic classification were performed on longitudinal stool samples to evaluate P3X engraftment. Differences in gastrointestinal microbiome composition were evaluated by principal coordinates analysis (PCoA) using Bray–Curtis dissimilarity based on species-level relative abundances. In both models, body weight, tumor burden by bioluminescence imaging (IVIS Lumina S5), and survival were monitored for up to 90 days following A20 inoculation. 

Results 

Among 566 patients, peri-infusion β-lactam antibiotic exposure was associated with worse OS (adjusted P=0.0025). Consistent with the clinical findings, ampicillin- and enrofloxacin-treated mice had significantly reduced OS (n=15 per group, P < 0.00001) and higher bone marrow tumor burden (P < 0.05) than water-treated controls. In addition, CAR-T cell frequencies were reduced in the bone marrow, liver, and spleen, while frequencies of CD8⁺PD-1⁺TIGIT⁺ and CD4⁺PD-1⁺TIGIT⁺ CAR-T cells were significantly increased (P<0.05), consistent with an exhausted CAR-T phenotype. 

We established an in vivo model for LBP-mediated microbiome restoration during CAR-T therapy in which successful engraftment of the P3X consortium required antibiotic conditioning. Following antibiotic conditioning and oral administration of P3X, all 13 species were detected at multiple time points, indicating successful colonization of the murine gastrointestinal tract. Importantly, P3X persisted following sublethal irradiation and A20 lymphoma inoculation, demonstrating stable engraftment under experimental conditions required for CAR-T studies. P3X administration alone did not alter A20 tumor growth, indicating no baseline antitumor or protumor effects. Bray–Curtis dissimilarity showed that the microbiome composition in mice receiving antibiotic conditioning and oral administration of P3X was distinct from baseline and characterized by increased P3X species relative abundance. In a preliminary CAR-T efficacy study, Finally, P3X-treated mice demonstrated improved survival and reduced tumor burden compared with the CAR-T control group (n= 10 per group, overall log-rank P < 0.05). 

Conclusions 

Clinical and preclinical findings identify β-lactam antibiotic-associated microbiome disruption as a potential contributor to impaired CAR-T efficacy. We established an in vivo model for LBP-mediated microbiome restoration and found that P3X-LBP can enhance CAR-T activity in vivo.  

Nathan Duong, BS: No relevant conflicts of interest to declare.